Amyloid-β suppresses AMP-activated protein kinase (AMPK) signaling and contributes to α-synuclein-induced cytotoxicity

Experimental Neurology

Volumn 275, Issue , 2016, Pages 84-98

  Lin, Chih Li ^a,b   Cheng, Yu Shih ^a   Li, Hsin Hua ^a   Chiu, Pai Yi ^a,c   Chang, Yen Ting ^a   Ho, Ying Jui ^a,b   Lai, Te Jen ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

AMP activated protein kinase; Amyloid ; Dementia with Lewy bodies; Sirtuin 1; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; AUTOPHAGY PROTEIN 12; AUTOPHAGY PROTEIN 5; AUTOPHAGY PROTEIN 7; CASPASE 3; COPPER ZINC SUPEROXIDE DISMUTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PEPTIDES AND PROTEINS; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DOWN REGULATION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; GENETICS; METABOLISM; MITOCHONDRION; NERVE CELL; PHYSIOLOGY; TUMOR CELL LINE; WISTAR RAT;

ALPHA-SYNUCLEIN; AMP-ACTIVATED PROTEIN KINASES; AMYLOID BETA-PEPTIDES; ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; LEWY BODY DISEASE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NEURONS; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84946854948     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.10.009     Document Type: Article

References (50)

1. Aldrin-Kirk P., Davidsson M., Holmqvist S., Li J.Y., Bjorklund T. Novel AAV-based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneurons. PLoS One 2014, 9.
2. Aoki R., Li Y.R. Alpha-synuclein promotes neuroprotection through NF-kappaB-mediated transcriptional regulation of protein kinase Cdelta. Sci. Signal. 2011, 4:jc6.
3. Bachhuber T., Katzmarski N., McCarter J.F., Loreth D., Tahirovic S., Kamp F., Abou-Ajram C., Nuscher B., Serrano-Pozo A., Muller A., Prinz M., Steiner H., Hyman B.T., Haass C., Meyer-Luehmann M. Inhibition of amyloid-beta plaque formation by alpha-synuclein. Nat. Med. 2015, 21:802-807.
4. Butterfield D.A., Swomley A.M., Sultana R. Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid. Redox Signal. 2013, 19:823-835.
5. Chan T., Chow A.M., Cheng X.R., Tang D.W., Brown I.R., Kerman K. Oxidative stress effect of dopamine on alpha-synuclein: electroanalysis of solvent interactions. ACS Chem. Neurosci. 2012, 3:569-574.
6. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 2002, 277:32046-32053.
7. Dulovic M., Jovanovic M., Xilouri M., Stefanis L., Harhaji-Trajkovic L., Kravic-Stevovic T., Paunovic V., Ardah M.T., El-Agnaf O.M., Kostic V., Markovic I., Trajkovic V. The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. Neurobiol. Dis. 2014, 63:1-11.
8. Emmer K.L., Covy J.P., Giasson B.I. Studies of protein aggregation in A53T alpha-synuclein transgenic, Tg2576 transgenic, and P246L presenilin-1 knock-in cross bred mice. Neurosci. Lett. 2012, 507:137-142.
9. Fecto F., Esengul Y.T., Siddique T. Protein recycling pathways in neurodegenerative diseases. Alzheimers Res. Ther. 2014, 6:13.
10. Fujishiro H., Iseki E., Nakamura S., Kasanuki K., Chiba Y., Ota K., Murayama N., Sato K. Dementia with Lewy bodies: early diagnostic challenges. Psychogeriatrics 2013, 13:128-138.
11. Furuya T.K., da Silva P.N., Payao S.L., Rasmussen L.T., de Labio R.W., Bertolucci P.H., Braga I.L., Chen E.S., Turecki G., Mechawar N., Mill J., de Arruda Cardoso Smith M. SORL1 and SIRT1 mRNA expression and promoter methylation levels in aging and Alzheimer's disease. Neurochem. Int. 2012, 61:973-975.
12. Godoy J.A., Rios J.A., Zolezzi J.M., Braidy N., Inestrosa N.C. Signaling pathway cross talk in Alzheimer's disease. Cell Commun. Signal. 2014, 12:23.
13. Hasegawa K., Wakino S., Yoshioka K., Tatematsu S., Hara Y., Minakuchi H., Washida N., Tokuyama H., Hayashi K., Itoh H. Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem. Biophys. Res. Commun. 2008, 372:51-56.
14. Hishikawa N., Hashizume Y., Yoshida M., Sobue G. Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol. 2003, 105:341-350.
15. Hong D.P., Xiong W., Chang J.Y., Jiang C. The role of the C-terminus of human alpha-synuclein: intra-disulfide bonds between the C-terminus and other regions stabilize non-fibrillar monomeric isomers. FEBS Lett. 2011, 585:561-566.
16. Hori Y.S., Kuno A., Hosoda R., Horio Y. Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS One 2013, 8.
17. Hsieh M.H., Gu S.L., Ho S.C., Pawlak C.R., Lin C.L., Ho Y.J., Lai T.J., Wu F.Y. Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model. Behav. Brain Res. 2012, 229:41-47.
18. Ihara M., Yamasaki N., Hagiwara A., Tanigaki A., Kitano A., Hikawa R., Tomimoto H., Noda M., Takanashi M., Mori H., Hattori N., Miyakawa T., Kinoshita M. Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron 2007, 53:519-533.
19. Kawamoto Y., Ito H., Ayaki T., Takahashi R. Immunohistochemical localization of apoptosome-related proteins in Lewy bodies in Parkinson's disease and dementia with Lewy bodies. Brain Res. 2014, 1571:39-48.
20. Kim W.S., Kagedal K., Halliday G.M. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res. Ther. 2014, 6:73.
21. Ko L.W., Ko H.H., Lin W.L., Kulathingal J.G., Yen S.H. Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells. J. Neuropathol. Exp. Neurol. 2008, 67:1084-1096.
22. Komatsu M., Waguri S., Chiba T., Murata S., Iwata J., Tanida I., Ueno T., Koike M., Uchiyama Y., Kominami E., Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
23. Kotzbauer P.T., Trojanowsk J.Q., Lee V.M. Lewy body pathology in Alzheimer's disease. J. Mol. Neurosci. MN 2001, 17:225-232.
24. Maetzler W., Liepelt I., Reimold M., Reischl G., Solbach C., Becker C., Schulte C., Leyhe T., Keller S., Melms A., Gasser T., Berg D. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol. Dis. 2009, 34:107-112.
25. Malkus K.A., Tsika E., Ischiropoulos H. Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol. Neurodegener. 2009, 4:24.
26. Marsh S.E., Blurton-Jones M. Examining the mechanisms that link beta-amyloid and alpha-synuclein pathologies. Alzheimers Res. Ther. 2012, 4:11.
27. Mayo M.C., Bordelon Y. Dementia with Lewy bodies. Semin. Neurol. 2014, 34:182-188.
28. McKeith I.G. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J. Alzheimers Dis. JAD 2006, 9:417-423.
29. Meeus B., Verstraeten A., Crosiers D., Engelborghs S., Van den Broeck M., Mattheijssens M., Peeters K., Corsmit E., Elinck E., Pickut B., Vandenberghe R., Cras P., De Deyn P.P., Van Broeckhoven C., Theuns J. DLB and PDD: a role for mutations in dementia and Parkinson disease genes?. Neurobiol. Aging 2012, 33:629.e5-629.e18.
30. Mullin S., Schapira A. Alpha-synuclein and mitochondrial dysfunction in Parkinson's disease. Mol. Neurobiol. 2013, 47:587-597.
31. Navarro A., Boveris A., Bandez M.J., Sanchez-Pino M.J., Gomez C., Muntane G., Ferrer I. Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies. Free Radic. Biol. Med. 2009, 46:1574-1580.
32. Nilsson P., Saido T.C. Dual roles for autophagy: degradation and secretion of Alzheimer's disease Abeta peptide. BioEssays 2014, 36:570-578.
33. Ono K., Yamada M. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J. Neurochem. 2006, 97:105-115.
34. Ozansoy M., Basak A.N. The central theme of Parkinson's disease: alpha-synuclein. Mol. Neurobiol. 2013, 47:460-465.
35. Park H., Kam T.I., Kim Y., Choi H., Gwon Y., Kim C., Koh J.Y., Jung Y.K. Neuropathogenic role of adenylate kinase-1 in Abeta-mediated tau phosphorylation via AMPK and GSK3beta. Hum. Mol. Genet. 2012, 21:2725-2737.
36. Paulson H.L., Igo I. Genetics of dementia. Semin. Neurol. 2011, 31:449-460.
37. Perez-Revuelta B.I., Hettich M.M., Ciociaro A., Rotermund C., Kahle P.J., Krauss S., Di Monte D.A. Metformin lowers Ser-129 phosphorylated alpha-synuclein levels via mTOR-dependent protein phosphatase 2A activation. Cell Death Dis. 2014, 5:e1209.
38. Pimentel C., Batista-Nascimento L., Rodrigues-Pousada C., Menezes R.A. Oxidative stress in Alzheimer's and Parkinson's diseases: insights from the yeast Saccharomyces cerevisiae. Oxidative Med. Cell. Longev. 2012, 2012:132146.
39. Pletnikova O., West N., Lee M.K., Rudow G.L., Skolasky R.L., Dawson T.M., Marsh L., Troncoso J.C. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol. Aging 2005, 26:1183-1192.
40. Poehler A.M., Xiang W., Spitzer P., May V.E., Meixner H., Rockenstein E., Chutna O., Outeiro T.F., Winkler J., Masliah E., Klucken J. Autophagy modulates SNCA/alpha-synuclein release, thereby generating a hostile microenvironment. Autophagy 2014, 10:2171-2192.
41. Pukass K., Richter-Landsberg C. Oxidative stress promotes uptake, accumulation, and oligomerization of extracellular alpha-synuclein in oligodendrocytes. J. Mol. Neurosci. MN 2014, 52:339-352.
42. Salminen A., Kaarniranta K. AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network. Ageing Res. Rev. 2012, 11:230-241.
43. Salminen A., Kaarniranta K., Kauppinen A. Crosstalk between oxidative stress and SIRT1: impact on the aging process. Int. J. Mol. Sci. 2013, 14:3834-3859.
44. Scarlata S., Golebiewska U. Linking alpha-synuclein properties with oxidation: a hypothesis on a mechanism underlying cellular aggregation. J. Bioenerg. Biomembr. 2014, 46:93-98.
45. Schulz-Schaeffer W.J. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010, 120:131-143.
46. Silva D.F., Esteves A.R., Arduino D.M., Oliveira C.R., Cardoso S.M. Amyloid-beta-induced mitochondrial dysfunction impairs the autophagic lysosomal pathway in a tubulin dependent pathway. J. Alzheimers Dis. JAD 2011, 26:565-581.
47. Tanaka K., Matsuda N. Proteostasis and neurodegeneration: the roles of proteasomal degradation and autophagy. Biochim. Biophys. Acta 2014, 1843:197-204.
48. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D.A., Kondo J., Ihara Y., Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:11282-11286.
49. Vefring H., Haugarvoll K., Tysnes O.B., Larsen J.P., Kurz M.W. The role of APOE alleles in incident Parkinson's disease. The Norwegian ParkWest Study. Acta Neurol. Scand. 2010, 122:438-441.
50. Wang Y., Yu Z., Ren H., Wang J., Wu J., Chen Y., Ding Z. The synergistic effect between beta-amyloid(1-42) and alpha-synuclein on the synapses dysfunction in hippocampal neurons. J. Chem. Neuroanat. 2015, 63:1-5.